NUVB · Nuvation Bio Inc. · Metrics
Market Cap
$2.29B
Shares
351.12M
NUVB metrics
65 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$6.52
Market cap
$2.29B
Price action
20 metricsPrice change (1W)
-0.5%
Price change (30D)
+0.2%
Price change (3M)
+34.1%
Price change (6M)
+40.9%
Price change (YTD)
-26.2%
Price change (1Y)
+89.4%
Trailing year
Price change (5Y)
-27.1%
52-week high
$9.54
52-week low
$3.01
Change from 52-week high
-30.7%
Change from 52-week low
+119.6%
Annualized volatility
85.6%
Annualized volatility (3M)
62.1%
Beta
1.7
RSI (14D)
49.6
Price vs SMA 50
+3.8%
Price vs SMA 200
+10.8%
Avg volume (3M)
6.77M
Relative volume
0.4
Average dollar volume
$41.24M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
351.12M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
11.0×
reciprocal yield 9.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
13.5×
reciprocal yield 7.4%
P / book
9.0
reciprocal yield 11.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
21.3×
reciprocal yield 4.7%
EV / revenue historical average (5Y)
21.3×
reciprocal yield 4.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
-81.0%
Trailing 12 months
Net margin
-88.2%
Gross profit (TTM)
$14.51M
Operating profit (TTM)
−$137.63M
Net income (TTM)
−$149.83M
Trailing 12 months
Diluted EPS (TTM)
$-0.44
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+555.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$169.90M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-59.0%
Return on assets
-20.1%
Debt / equity
1.0
Current ratio
8.4
EBITDA (TTM)
−$135.48M
Free cash flow (TTM)
—
Quick ratio
8.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$412.44M
Latest balance sheet
Cash & equivalents
$258.60M
Total assets
$744.50M
Total debt
$248.52M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$120.52M
Capital expenditures (TTM)
—
R&D (TTM)
$128.85M
SG&A (TTM)
$158.59M
Stock compensation (TTM)
$35.50M
R&D / revenue
75.8%
Stock compensation / revenue
20.9%
Ownership (13F)
3 metrics13F filers
243
13F filer change QoQ
+8
Institutional ownership
68.3%
Short interest
3 metricsShort interest
15.2%
Latest settlement · 8.9 days to cover
Days to cover
8.9d
Short-squeeze score
83 / 100
Insider activity
2 metricsNet insider buying (90D)
−$2.13M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1811063
CUSIP
67080N101
13F (30d)
152 filings
152 filers
Visit website
Investor relations